sur Jaguar Health, Inc. (NASDAQ:JAGX)
Jaguar Health's Q2 2025 Financial Growth and Future Plans
San Francisco-based Jaguar Health, Inc. reported a 35% increase in net revenue for Q2 2025, reaching approximately $3.0 million compared to $2.2 million in Q1 2025. This significant growth also reflects a 10% rise over the same period in 2024. A notable increase was observed in the Mytesi prescription volume by 6.5% in Q2 2025 compared to Q1 2025, maintaining the same level as Q2 2024.
The company emphasized advancements in their research with positive proof-of-concept results for their product crofelemer. Their regulatory path plans to include patients with metastatic breast cancer, aligned with orphan drug criteria in the US. Jaguar Health's strategy remains focused on seeking partnerships for non-dilutive funding through licensing its orphan indication products. A webcast will be held to discuss these updates and their financial results.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Jaguar Health, Inc.